AnaptysBio enters the week in a striking tension: short interest has climbed to a meaningful 17.5% of free float while options traders have pivoted to their most bullish posture in months — a split that makes the next catalyst unusually charged.
The positioning story is the clearest tension in the data right now. Short interest has been building steadily, rising 16.5% over the past month to 4.83 million shares, or 17.5% of the free float. That is a genuinely elevated level for a biotech of this size, and the trend has accelerated across June — up roughly 1.2% in shares this week alone. Yet the borrow market tells a different story: availability remains loose at 1,178% of current short interest, meaning there are roughly twelve shares available to lend for every one already out on loan. Cost to borrow has crept up 6.7% on the week but remains negligible at 0.48% — this is not a market pricing in squeeze risk. The ORTEX short score has edged up to 60.4, its highest in the tracked window, consistent with bears maintaining conviction rather than retreating. The jarring contrast is in options: the put/call ratio collapsed to 0.16 on June 9 from 2.27 the prior session — a move almost one standard deviation below the 20-day mean of 3.79. That's a dramatic single-session shift toward calls, suggesting at least some participants are positioning for a sharp move higher, even as shorts hold their ground.
The Street is broadly constructive, though the path has been volatile. HC Wainwright initiated fresh coverage this week with a Buy and a $95 target — the most bullish on the Street. UBS and Barclays both raised targets in mid-May after cutting them sharply in late April, with UBS moving from $60 to $76 and Barclays from $63 to $75. The mean target of $87 implies roughly 69% upside from the current $51.63 — a gap that reflects how far the stock has fallen from earlier-year levels. ANAB is down 25.5% over the past month despite a small 0.7% recovery this week. The bull case centers on imsidolimab and ANB033 in GPP, celiac, and EoE — a pipeline with genuine differentiation in inflammation. The bear case points to execution risk, competition in the broader IL-33/IL-4 space, and royalty dependency on arrangements that carry litigation exposure. Factor scores add nuance: EPS surprise ranks in the 94th percentile and analyst recommendation divergence scores in the 92nd, suggesting the Street is more uniformly positive than the short positioning implies. Value remains stretched — P/B has compressed sharply, falling 5.6 points over 30 days to 11.2, but the EV/EBITDA of 9.9 has drifted modestly higher.
Institutional ownership offers one interesting data point. Sirenia Capital Management entered as the largest disclosed holder with a 6.6% stake — the entire position was new as of the March 31 filing. FMR (Fidelity) added 445,000 shares in the most recent period, a meaningful add relative to its prior position. On the other side, Millennium cut its position by 338,000 shares and D.E. Shaw trimmed by 91,000. Insider activity, all of which predates the recent sell-off, was entirely on the sell side — CEO Daniel Faga disposed of roughly 14,000 shares in late March at prices between $57 and $65, meaningfully above today's $51.63.
Earnings history adds to the complexity. The last two prints both triggered negative reactions — a 7.7% one-day drop on May 12 and a 5.5% decline on May 15 — while the two preceding reports saw double-digit five-day gains. The next event is August 5. That date sits far enough out that it is not the immediate driver of this week's options shift, making the call-heavy posture more likely tied to a near-term catalyst expectation — clinical data, a partnership update, or a broader biotech sentiment move — rather than earnings positioning.
What to watch: whether the gap between a PCR near zero and a short interest near 17.5% of float closes from the short side (shorts covering) or the long side (calls expiring worthless), and whether any data readout on imsidolimab or ANB033 surfaces ahead of the August earnings date to resolve the divergence.
See the live data behind this article on ORTEX.
Open ANAB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
